SCHEMBL336940

SCHEMBL336940

CCOC(=O)C1CCC2(C1)OCCCO2

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
TP53 P04637 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 6/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36
PPM1B O75688 1/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2680062 0.94 CYP3A4 (0.45) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL1654619 0.88 CYP3A4 (0.48) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL13308632 0.88 CYP3A4 (0.48) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL5618 0.84 CYP3A4 (0.49) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL14127636 0.80 CYP3A4 (0.45) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL22898114 0.78 ALDH1A1 (0.44) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL7878595 0.78 ALDH1A1 (0.41) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL31546015 0.77 ALDH1A1 (0.39) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL584691 0.77 GAA (0.39) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2
SCHEMBL16908082 0.76 ALDH1A1 (0.42) CYP3A4CYP2C19TP53MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097637-B2 Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors HOFFMANN-LA ROCHE INC. (US) 2012-01-17 US disclosed
EP-2185513-B1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-20090042943-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HOFFMANN-LA ROCHE, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042943-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HTR2A, HTR3A, HTR5A CYP3A4 1513/4885CYP2C19 481/4885TP53 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.